BMRA (Biomerica) Beginning Cash Position: $2.52 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRA Biomerica Inc BMRA
50 GF Score
Price $1.59
GF Value $2.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Biomerica Beginning Cash Position?

Biomerica BMRA +2.58% 50 Beginning Cash Position is $2.52 Mil as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Biomerica's Beginning Cash Position for the quarter that ended in Feb. 2026 was $2.52 Mil.

Biomerica's quarterly Beginning Cash Position increased from Aug. 2025 ($2.40 Mil) to Nov. 2025 ($3.05 Mil) but then declined from Nov. 2025 ($3.05 Mil) to Feb. 2026 ($2.52 Mil).

Biomerica's annual Beginning Cash Position increased from May. 2023 ($5.92 Mil) to May. 2024 ($9.72 Mil) but then declined from May. 2024 ($9.72 Mil) to May. 2025 ($4.17 Mil).

Biomerica Beginning Cash Position Related Terms

Biomerica Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Biomerica's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica Beginning Cash Position Chart

Biomerica Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.64 4.20 5.92 9.72 4.17

Biomerica Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 3.06 2.40 3.05 2.52
BMRA
50GF Score
Biomerica Inc BMRA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomerica Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.52 Mil mean?
Biomerica (BMRA) has a Beginning Cash Position of $2.52 Mil as of Feb. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Biomerica and its competitors.
Is Biomerica's Beginning Cash Position too high?
Biomerica's current Beginning Cash Position is $2.52 Mil. Overall, Biomerica has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Beginning Cash Position compare to WOK and ALURD?
Biomerica's Beginning Cash Position of $2.52 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Biomerica and its competitors. Biomerica's current Beginning Cash Position is $2.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.18, compared to a current price of $1.59 — trading 27.1% below its estimated fair value. The current Beginning Cash Position is $2.52 Mil. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Biomerica (BMRA), the current Beginning Cash Position is $2.52 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomerica (BMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Biomerica stock appears to be undervalued. The current stock price of $1.59 is trading 27.1% below its estimated GF Value™ of $2.18. GuruFocus considers Biomerica to be Modestly Undervalued.

Key valuation signals for BMRA:

  • Beginning Cash Position: $2.52 Mil
  • GF Value™: $2.18 vs. price of $1.59 (27.1% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biomerica Business Description

Address 17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score

Get the complete analysis for BMRA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price
$2.18
GF Value